{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:28:21Z","timestamp":1775341701001,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BMBF","award":["03V0396"],"award-info":[{"award-number":["03V0396"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking, the identification of combination-induced molecular mechanisms bears significant value for the further development of interventional approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Combined application of conventional cytostatic agents (cytarabine and dexamethasone) with the PI3K-inhibitor Idelalisib was analysed on cell-biologic parameters in two acute pro-B lymphoblastic leukaemia (B-ALL) cell lines. In particular, for comparative characterisation of the molecular signatures induced by the combined and mono application, whole transcriptome sequencing was performed. Emphasis was placed on pathways and genes exclusively regulated by drug combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Idelalisib\u2009+\u2009cytostatics combinations changed pathway activation for, e.g., \u201cRetinoblastoma in cancer\u201d, \u201cTGF-b signalling\u201d, \u201cCell cycle\u201d and \u201cDNA-damage response\u201d to a greater extent than the two cytostatics alone. Analyses of the top-20 regulated genes revealed that both combinations induce characteristic gene expression changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A specific set of genes was exclusively deregulated by the drug combinations, matching the combination-specific anti-proliferative cell-biologic effects. The addition of Idelalisib suggests minor synergistic effects which are rather to be classified as additive.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12935-020-01431-4","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:03:47Z","timestamp":1597233827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines"],"prefix":"10.1186","volume":"20","author":[{"given":"L.-M.","family":"Sklarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. S.","family":"Gladbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Roolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Struckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fuellen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-7986","authenticated-orcid":false,"given":"H.","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"1431_CR1","doi-asserted-by":"publisher","first-page":"E147","DOI":"10.1188\/16.CJON.E147-E154","volume":"20","author":"S Jacobson","year":"2016","unstructured":"Jacobson S, Tedder M, Eggert J. Adult acute lymphoblastic leukemia: a genetic overview and application to clinical practice. Clin J Oncol Nurs. 2016;20:E147\u201354.","journal-title":"Clin J Oncol Nurs."},{"key":"1431_CR2","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","volume":"125","author":"M M\u00fcschen","year":"2015","unstructured":"M\u00fcschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015;125:3688\u201393.","journal-title":"Blood."},{"key":"1431_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0506-4","volume":"36","author":"N Cruz-Rodriguez","year":"2017","unstructured":"Cruz-Rodriguez N, Combita AL, Enciso LJ, Raney LF, Pinzon PL, Lozano OC, et al. Prognostic stratification improvement by integrating ID1\/ID3\/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL. J Exp Clin Cancer Res. 2017;36:1\u201312.","journal-title":"J Exp Clin Cancer Res."},{"key":"1431_CR4","unstructured":"Adult Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae)\u2013Health Professional Version https:\/\/www.cancer.gov\/types\/leukemia\/hp\/adult-all-treatment-pdq#link\/_34_toc."},{"key":"1431_CR5","doi-asserted-by":"crossref","unstructured":"Winters AC, Bernt KM. MLL-Rearranged Leukemias\u2014An Update on Science and Clinical Approaches. Front Pediatr. 2017;5:11\u20133. http:\/\/journal.frontiersin.org\/article\/10.3389\/fped.2017.00004\/full.","DOI":"10.3389\/fped.2017.00004"},{"key":"1431_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(12)62187-4.","journal-title":"Lancet"},{"key":"1431_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2013.245","volume":"28","author":"JAP Spijkers-Hagelstein","year":"2014","unstructured":"Spijkers-Hagelstein JAP, Pinhan\u00e7os SS, Schneider P, Pieters R, Stam RW. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia. 2014;28:761\u20139.","journal-title":"Leukemia"},{"key":"1431_CR8","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Acute lymphoblastic leukaemia in adult patients: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69\u201382.","journal-title":"Ann Oncol"},{"issue":"1","key":"1431_CR9","doi-asserted-by":"publisher","first-page":"e2014007","DOI":"10.4084\/mjhid.2014.007","volume":"6","author":"T Sacha","year":"2014","unstructured":"Sacha T. Imatinib in chronic myeloid leukemia : an overview. Mediterr J Hematol Infect Dis. 2014;6(1):e2014007.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1431_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"M Barrett","year":"2017","unstructured":"Barrett M, Foa R, Brien SO, Valente N, Wenger M, Maloney DG. Rituximab in B-cell hematologic malignancies : a review of 20 years of clinical experience. Adv Ther. 2017;34:2232\u201373.","journal-title":"Adv Ther."},{"key":"1431_CR11","doi-asserted-by":"crossref","unstructured":"Burger JA, Okkenhaug K. Idelalisib\u2014targeting PI3K\u03b4 in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014;11:184\u20136. http:\/\/www.nature.com\/articles\/nrclinonc.2014.42.","DOI":"10.1038\/nrclinonc.2014.42"},{"key":"1431_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","volume":"95","author":"SC Howard","year":"2016","unstructured":"Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol. 2016;95:563\u201373.","journal-title":"Ann Hematol"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJMe1400055","volume":"370","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Cantley LC. Idelalisib\u2014A PI3K\u03b4 inhibitor for B-cell cancers. N Engl J Med. 2014;370:1061\u20132. https:\/\/doi.org\/10.1056\/NEJMe1400055.","journal-title":"N Engl J Med."},{"key":"1431_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2146\/ajhp150281","volume":"73","author":"B Do","year":"2016","unstructured":"Do B, Mace M, Rexwinkle A. Idelalisib for treatment of B-cell malignancies. Am J Heal Pharm. 2016;73:547\u201355.","journal-title":"Am J Heal Pharm."},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood-2017-02-766204","volume":"129","author":"KA Kruth","year":"2017","unstructured":"Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. 2017;129:3000\u20138.","journal-title":"Blood"},{"key":"1431_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med."},{"key":"1431_CR17","unstructured":"Food and Drug Administration; FDA. ZYDELIG (idelalisib). 2014;44:1\u201325. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205858lbl.pdf."},{"key":"1431_CR18","unstructured":"Zydelig idelalisib European Medicines Agency. https:\/\/imedikament.de\/zydelig."},{"key":"1431_CR19","doi-asserted-by":"crossref","unstructured":"Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S, et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer. BioMed Central Ltd; 2010;10:560. http:\/\/www.biomedcentral.com\/1471-2407\/10\/560.","DOI":"10.1186\/1471-2407-10-560"},{"key":"1431_CR20","doi-asserted-by":"crossref","unstructured":"Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K\/AKT\/mTOR inhibition in acute leukemia. Mol Cell Ther. 2015;3:2. http:\/\/www.molcelltherapies.com\/content\/3\/1\/2.","DOI":"10.1186\/s40591-015-0040-8"},{"key":"1431_CR21","doi-asserted-by":"crossref","unstructured":"Silveira AB, Laranjeira ABA, Rodrigues GOL, Leal R, Cardoso BA, Barata JT, et al. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Oncotarget. 2015;6:13105\u201318. http:\/\/www.impactjournals.com\/oncotarget\/index.php?journal=oncotarget&page=article&op=view&path[]=3524&path[]=8569.","DOI":"10.18632\/oncotarget.3524"},{"key":"1431_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/leu.2013.226","volume":"28","author":"LM Neri","year":"2014","unstructured":"Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, et al. Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2014;28:739\u201348. https:\/\/doi.org\/10.1038\/leu.2013.226.","journal-title":"Leukemia."},{"key":"1431_CR23","doi-asserted-by":"publisher","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","volume":"7","author":"XM Zhao","year":"2011","unstructured":"Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol. 2011;7:e1002323.","journal-title":"PLoS Comput Biol."},{"issue":"12","key":"1431_CR24","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.3390\/ijms20122929","volume":"20","author":"N Coccaro","year":"2019","unstructured":"Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Next-generation sequencing in acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(12):2929.","journal-title":"Int J Mol Sci."},{"key":"1431_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc2169","volume":"7","author":"R Boutros","year":"2007","unstructured":"Boutros R, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7:5\u20137.","journal-title":"Nat Rev Cancer."},{"key":"1431_CR26","doi-asserted-by":"crossref","unstructured":"Xiong X, Qiu F, Fang J, Shen Y, Liang C, Jiang W, et al. Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. 2009;662:10\u20135.","DOI":"10.1016\/j.mrfmmm.2008.11.014"},{"key":"1431_CR27","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.1007\/s13277-014-2527-3","volume":"35","author":"X Tan","year":"2014","unstructured":"Tan X, Chen M. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. Tumor Biol. 2014;35:12189\u2013200.","journal-title":"Tumor Biol."},{"key":"1431_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/1471-2164-15-416","volume":"15","author":"NC Wong","year":"2014","unstructured":"Wong NC, Bhadri VA, Maksimovic J, Parkinson-Bates M, Ng J, Craig JM, et al. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics. 2014;15:416.","journal-title":"BMC Genomics."},{"key":"1431_CR29","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/onc.2009.455","volume":"29","author":"M Cheung","year":"2010","unstructured":"Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene. 2010;29:1633\u201340.","journal-title":"Oncogene."},{"key":"1431_CR30","doi-asserted-by":"crossref","unstructured":"Lee S, Jeon H, Kim C, Ju M, Bae H, Park H, et al. Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis. Mol Cancer. 2011;10:113. http:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-10-113.","DOI":"10.1186\/1476-4598-10-113"},{"key":"1431_CR31","doi-asserted-by":"publisher","first-page":"E623","DOI":"10.1002\/ijc.29169","volume":"136","author":"L Gao","year":"2015","unstructured":"Gao L, Ma J, Mannoor K, Guarnera MA, Shetty A, Zhan M, et al. Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. Int J Cancer. 2015;136:E623\u20139.","journal-title":"Int J Cancer"},{"key":"1431_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1158\/0008-5472.CAN-10-1704","volume":"71","author":"AJ Lilly","year":"2011","unstructured":"Lilly AJ, Khanim FL, Hayden RE, Luong QT, Drayson MT, Bunce CM. Nm23-H1 Indirectly promotes the survival of acute myeloid leukemia blast cells by binding to more mature components of the leukemic clone. Cancer Res. 2011;71:1177\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1704.","journal-title":"Cancer Res."},{"key":"1431_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2045-3701-1-6","volume":"1","author":"C-P Chan","year":"2011","unstructured":"Chan C-P, Kok K-H, Jin D-Y. CREB3 subfamily transcription factors are not created equal: recent insights from global analyses and animal models. Cell Biosci. 2011;1:6.","journal-title":"Cell Biosci."},{"key":"1431_CR34","doi-asserted-by":"publisher","first-page":"e1026534","DOI":"10.1080\/2162402X.2015.1026534","volume":"4","author":"M Janakiram","year":"2015","unstructured":"Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology. 2015;4:e1026534.","journal-title":"Oncoimmunology."},{"key":"1431_CR35","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.7314\/APJCP.2014.15.8.3805","volume":"15","author":"E Floriano-Sanchez","year":"2014","unstructured":"Floriano-Sanchez E, Rodriguez NC, Bandala C, Coballase-Urrutia E, Lopez-Cruz J. CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev. 2014;15:3805\u20139.","journal-title":"Asian Pac J Cancer Prev."},{"key":"1431_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bbrc.2012.10.123","volume":"429","author":"J Moreaux","year":"2012","unstructured":"Moreaux J, Kassambara A, Hose D, Klein B. STEAP1 is overexpressed in cancers: a promising therapeutic target. Biochem Biophys Res Commun. 2012;429:148\u201355.","journal-title":"Biochem Biophys Res Commun."},{"key":"1431_CR37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13277-014-2746-7","volume":"36","author":"Z Guo","year":"2015","unstructured":"Guo Z, Liu J, Zhang L, Su B, Xing Y, He Q, et al. KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma. Tumour Biol. 2015;36:1251\u20139.","journal-title":"Tumour Biol."},{"key":"1431_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.leu.2404525","volume":"21","author":"T Milde","year":"2007","unstructured":"Milde T, Shmelkov SV, Jensen KK, Zlotchenko G, Petit I, Rafii S. A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias. Leukemia. 2007;21:824\u20137.","journal-title":"Leukemia"},{"key":"1431_CR39","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1084\/jem.20151713","volume":"213","author":"H Uckelmann","year":"2016","unstructured":"Uckelmann H, Blaszkiewicz S, Nicolae C, Haas S, Schnell A, Wurzer S, et al. Extracellular matrix protein Matrilin-4 regulates stress-induced HSC proliferation via CXCR4. J Exp Med. 2016;213:1961\u201371.","journal-title":"J Exp Med"},{"key":"1431_CR40","doi-asserted-by":"publisher","first-page":"85068","DOI":"10.18632\/oncotarget.18844","volume":"8","author":"V Puddinu","year":"2017","unstructured":"Puddinu V, Casella S, Radice E, Thelen S, Dirnhofer S, Bertoni F, et al. ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. Oncotarget. 2017;8:85068\u201384.","journal-title":"Oncotarget."},{"key":"1431_CR41","doi-asserted-by":"publisher","first-page":"39033","DOI":"10.18632\/oncotarget.16559","volume":"8","author":"X Deng","year":"2017","unstructured":"Deng X, Tu Z, Xiong M, Tembo K, Zhou L, Liu P, et al. Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis. Oncotarget. 2017;8:39033\u201347.","journal-title":"Oncotarget."},{"key":"1431_CR42","doi-asserted-by":"publisher","first-page":"11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"J Li","year":"2018","unstructured":"Li J, Dai Y, Lilljebj\u00f6rn H, Shen S, Cui B, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1, 223 cases. Proc Nat Acad Sci. 2018;115:11711\u201320.","journal-title":"Proc Nat Acad Sci."},{"key":"1431_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0515-y","volume":"10","author":"Y Marincevic-zuniga","year":"2017","unstructured":"Marincevic-zuniga Y, Dahlberg J, Nilsson S, Raine A, Nystedt S, Lindqvist CM, et al. Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes associated with distinct DNA methylation profiles. J Hematol Oncol. 2017;10:1\u201314.","journal-title":"J Hematol Oncol"},{"key":"1431_CR44","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","volume":"107","author":"M Dong","year":"2006","unstructured":"Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107:4589\u201396.","journal-title":"Blood."},{"key":"1431_CR45","unstructured":"EIF5AL1 https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=EIF5AL1."},{"key":"1431_CR46","doi-asserted-by":"publisher","first-page":"53.e23","DOI":"10.1016\/j.urolonc.2013.08.028","volume":"32","author":"IM Gomes","year":"2014","unstructured":"Gomes IM, Arinto P, Lopes C, Santos CR, Maia CJ. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol. 2014;32:53.e23\u20135329.","journal-title":"Urol Oncol."},{"key":"1431_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jare.2013.10.002","volume":"5","author":"GT Ali","year":"2014","unstructured":"Ali GT, Al-Azhary NM, Mokhtar DA. Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia. J Adv Res. 2014;5:657\u201361.","journal-title":"J Adv Res."},{"key":"1431_CR48","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/nar\/gki332","volume":"33","author":"K-T Chin","year":"2005","unstructured":"Chin K-T, Zhou H-J, Wong C-M, Lee JM-F, Chan CP, Qiang B-Q, et al. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res. 2005;33:1859\u201373.","journal-title":"Nucleic Acids Res."},{"key":"1431_CR49","first-page":"463","volume":"32","author":"C Schult","year":"2012","unstructured":"Schult C, Dahlhaus M, Glass A, Fischer K, Lange S, Freund M, et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res. 2012;32:463\u201374.","journal-title":"Anticancer Res"},{"key":"1431_CR50","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/cas.13263","volume":"108","author":"C Xie","year":"2017","unstructured":"Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. Exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 2017;108:1476\u201384.","journal-title":"Cancer Sci."},{"key":"1431_CR51","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1096\/fj.13-229070","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Wang L, Guo S, Bao Y, Ma Y, Yan F, et al. Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers. FASEB J. 2013;27:4194\u2013203.","journal-title":"FASEB J."},{"key":"1431_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2329-6917.1000113","volume":"1","author":"A Shukla","year":"2013","unstructured":"Shukla A, Chaturvedi NK, Ahrens AK, Cutucache CE, Mittal AK, Bierman P, et al. Stromal tumor microenvironment in chronic lymphocytic leukemia: regulation of leukemic progression. J Leukemia. 2013;1:1\u20139.","journal-title":"J Leukemia"},{"key":"1431_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fonc.2018.00033","volume":"8","author":"L Weber","year":"2018","unstructured":"Weber L, Ma\u00dfberg D, Becker C, Altm\u00fcller J, Ubrig B, Bonatz G, et al. Olfactory receptors as biomarkers in human breast carcinoma tissues. Front Oncol. 2018;8:33.","journal-title":"Front Oncol."},{"key":"1431_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2015.70","author":"S Manteniotis","year":"2016","unstructured":"Manteniotis S, Wojcik S, Brauhoff P, M\u00f6llmann M, Petersen L, G\u00f6thert JR, et al. Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia. Nat Publ Gr. 2016. https:\/\/doi.org\/10.1038\/cddiscovery.2015.70.","journal-title":"Nat Publ Gr."},{"key":"1431_CR55","doi-asserted-by":"crossref","unstructured":"Milde T, Shmelkov S V, Jensen KK, Zlotchenko G, Petit I, Rafii S. A novel family of slitrk genes is expressed on hematopoietic stem cells and leukemias. Leukemia. 2007;21:824\u20137. http:\/\/www.nature.com\/articles\/2404525.","DOI":"10.1038\/sj.leu.2404525"},{"key":"1431_CR56","doi-asserted-by":"publisher","first-page":"e85926","DOI":"10.1371\/journal.pone.0085926","volume":"9","author":"CC Melo R de","year":"2014","unstructured":"Melo R de CC, Longhini AL, Bigarella CL, Baratti MO, Traina F, Favaro P, et al. CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. PLoS One. 2014;9:e85926.","journal-title":"PLoS One."},{"key":"1431_CR57","first-page":"1","volume":"11","author":"D Chen","year":"2016","unstructured":"Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sj\u00f6gren H, Abrahamsson J, et al. The expression pattern of the Pre-B cell receptor components correlates with cellular stage and clinical outcome in acute lymphoblastic leukemia. PLoS ONE. 2016;11:1\u201316.","journal-title":"PLoS ONE"},{"key":"1431_CR58","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s11427-015-4919-z","volume":"58","author":"C Huang","year":"2015","unstructured":"Huang C, Melnick A. Mechanisms of action of BCL6 during germinal center B cell development. Sci China Life Sci. 2015;58:1226\u201332.","journal-title":"Sci China Life Sci."},{"key":"1431_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nri3570","volume":"14","author":"MR Clark","year":"2014","unstructured":"Clark MR, Mandal M, Ochiai K, Singh H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol. 2014;14:69\u201380.","journal-title":"Nat Rev Immunol."},{"key":"1431_CR60","doi-asserted-by":"crossref","unstructured":"Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol. 2017;10:145. http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0512-1.","DOI":"10.1186\/s13045-017-0512-1"},{"key":"1431_CR61","unstructured":"Andrews S. FastQC: A quality control tool for high throughput sequence data. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"1431_CR62","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"key":"1431_CR63","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.","journal-title":"Genome Biol."},{"key":"1431_CR64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139.","journal-title":"Nat Methods"},{"key":"1431_CR65","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"1431_CR66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"1431_CR67","unstructured":"Carlson M. org.Hs.eg.db: Genome wide annotation for Human. R Packag version 312. 2015;."},{"key":"1431_CR68","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol."},{"key":"1431_CR69","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/nar\/gkv1024","volume":"44","author":"M Kutmon","year":"2016","unstructured":"Kutmon M, Riutta A, Nunes N, Hanspers K, Willighagen EL, Bohler A, et al. WikiPathways: capturing the full diversity of pathway knowledge. Nucleic Acids Res. 2016;44:488\u201394.","journal-title":"Nucleic Acids Res."},{"key":"1431_CR70","doi-asserted-by":"crossref","unstructured":"Pico AR, Kelder T, Van Iersel MP, Hanspers K, Conklin BR, Evelo C. WikiPathways: pathway editing for the people. PLoS Biol. 2008. p. 1403\u20137","DOI":"10.1371\/journal.pbio.0060184"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-020-01431-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-01431-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T17:51:22Z","timestamp":1667757082000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-01431-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-01431-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}